Large Ca Isotope Effect in CaC6

We have measured the Ca isotope effect in the newly discovered superconductor CaC6. The isotope effect coefficient is 0.50(7). If one assumes that this material is a conventional electron-phonon coupled superconductor, this result shows that the superconductivity is dominated by coupling of the electrons by Ca phonon modes and that C phonons contribute very little. Thus, in contrast to MgB2, where phonons in the B layers are responsible for the superconductivity, in CaC6 the phonons are primarily modes of the intercalated Ca.Comment: 11 pages including 2 Figure

Trials

OBJECTIVES: To assess the efficacy of several repurposed drugs to prevent hospitalisation or death in patients aged 65 or more with recent symptomatic SARS-CoV-2 infection (COVID-19) and no criteria for hospitalisation. TRIAL DESIGN: Phase III, multi-arm (5) and multi-stage (MAMS), randomized, open-label controlled superiority trial. Participants will be randomly allocated 1:1:1:1:1 to the following strategies: Arm 1: Control arm Arms 2 to 5: Experimental treatment arms Planned interim analyses will be conducted at regular intervals. Their results will be reviewed by an Independent Data and Safety Monitoring Board. Experimental arms may be terminated for futility, efficacy or toxicity before the end of the trial. New experimental arms may be added if new evidence suggests that other treatments should be tested. A feasibility and acceptability substudy as well as an immunological substudy will be conducted alongside the trial. PARTICIPANTS: Inclusion criteria are: 65-year-old or more; Positive test for SARS-CoV-2 on a nasopharyngeal swab; Symptoms onset within 3 days before diagnosis; No hospitalisation criteria; Signed informed consent; Health insurance. Exclusion criteria are: Inability to make an informed decision to participate (e.g.: dementia, guardianship); Rockwood Clinical Frailty Scale ≥7; Long QT syndrome; QTc interval > 500 ms; Heart rate 5.5 mmol/L or <3.5 mmol/L; Ongoing treatment with piperaquine, halofantrine, dasatinib, nilotinib, hydroxyzine, domperidone, citalopram, escitalopram, potent inhibitors or inducers of cytochrome P450 CYP3A4 isoenzyme, repaglinide, azathioprine, 6-mercaptopurine, theophylline, pyrazinamide, warfarin; Known hypersensitivity to any of the trial drugs or to chloroquine and other 4-aminoquinolines, amodiaquine, mefloquine, glafenine, floctafenine, antrafenine, ARB; Hepatic porphyria; Liver failure (Child-Pugh stage ≥B); Stage 4 or 5 chronic kidney disease (GFR <30 mL/min/1.73 m²); Dialysis; Hypersentivity to lactose; Lactase deficiency; Abnormalities in galactose metabolism; Malabsorption syndrome; Glucose-6-phosphate dehydrogenase deficiency; Symptomatic hyperuricemia; Ileus; Colitis; Enterocolitis; Chronic hepatitis B virus disease. The trial is being conducted in France in the Bordeaux, Corse, Dijon, Nancy, Paris and Toulouse areas as well as in the Grand Duchy of Luxembourg. Participants are recruited either at home, nursing homes, general practices, primary care centres or hospital outpatient consultations. INTERVENTION AND COMPARATOR: The four experimental treatments planned in protocol version 1.2 (April 8(th), 2020) are: (1) Hydroxychloroquine 200 mg, 2 tablets BID on day 0, 2 tablets QD from day 1 to 9; (2) Imatinib 400 mg, 1 tablet QD from day 0 to 9; (3) Favipiravir 200 mg, 12 tablets BID on day 0, 6 tablets BID from day 1 to 9; (4) Telmisartan 20 mg, 1 tablet QD from day 0 to 9. The comparator is a complex of vitamins and trace elements (AZINC Forme et Vitalité®), 1 capsule BID for 10 days, for which there is no reason to believe that they are active on the virus. In protocol version 1.2 (April 8th, 2020): People in the control arm will receive a combination of vitamins and trace elements; people in the experimental arms will receive hydroxychloroquine, or favipiravir, or imatinib, or telmisartan. MAIN OUTCOME: The primary outcome is the proportion of participants with an incidence of hospitalisation and/or death between inclusion and day 14 in each arm. RANDOMISATION: Participants are randomized in a 1:1:1:1:1 ratio to each arm using a web-based randomisation tool. Participants not treated with an ARB or ACEI prior to enrolment are randomized to receive the comparator or one of the four experimental drugs. Participants already treated with an ARB or ACEI are randomized to receive the comparator or one of the experimental drugs except telmisartan (i.e.: hydroxychloroquine, imatinib, or favipiravir). Randomisation is stratified on ACEI or ARBs treatment at inclusion and on the type of residence (personal home vs. nursing home). BLINDING (MASKING): This is an open-label trial. Participants, caregivers, investigators and statisticians are not blinded to group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): A total of 1057 participants will be enrolled if all arms are maintained until the final analysis and no additional arm is added. Three successive futility interim analyses are planned, when the number of participants reaches 30, 60 and 102 in the control arm. Two efficacy analyses (interim n°3 and final) will be performed successively. TRIAL STATUS: This describes the Version 1.2 (April 8(th), 2020) of the COVERAGE protocol that was approved by the French regulatory authority and ethics committee. The trial was opened for enrolment on April 15(th), 2020 in the Nouvelle Aquitaine region (South-West France). Given the current decline of the COVID-19 pandemic in France and its unforeseeable dynamic in the coming months, new trial sites in 5 other French regions and in Luxembourg are currently being opened. A revised version of the protocol was submitted to the regulatory authority and ethics committee on June 15(th), 2020. It contains the following amendments: (i) Inclusion criteria: age ≥65 replaced by age ≥60; time since first symptoms <3 days replaced by time since first symptoms <5 days; (ii) Withdrawal of the hydroxychloroquine arm (due to external data); (iii) increase in the number of trial sites. TRIAL REGISTRATION: The trial was registered on Clinical Trials.gov on April 22(nd), 2020 (Identifier: NCT04356495): and on EudraCT on April 10(th), 2020 (Identifier: 2020-001435-27). FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2)

Midlife managerial experience is linked to late life hippocampal morphology and function

An active cognitive lifestyle has been suggested to have a protective role in the long-term maintenance of cognition. Amongst healthy older adults, more managerial or supervisory experiences in midlife are linked to a slower hippocampal atrophy rate in late life. Yet whether similar links exist in individuals with Mild Cognitive Impairment (MCI) is not known, nor whether these differences have any functional implications. 68 volunteers from the Sydney SMART Trial, diagnosed with non-amnestic MCI, were divided into high and low managerial experience (HME/LME) during their working life. All participants underwent neuropsychological testing, structural and resting-state functional MRI. Group comparisons were performed on hippocampal volume, morphology, hippocampal seed-based functional connectivity, memory and executive function and self-ratings of memory proficiency. HME was linked to better memory function (p = 0.024), mediated by larger hippocampal volume (p = 0.025). More specifically, deformation analysis found HME had relatively more volume in the CA1 sub-region of the hippocampus (p  <  0.05). Paradoxically, this group rated their memory proficiency worse (p = 0.004), a result correlated with diminished functional connectivity between the right hippocampus and right prefrontal cortex (p  <  0.001). Finally, hierarchical regression modelling substantiated this double dissociation

Experimental study of coupled electron-ripplon vibrations of the 2D electron crystal at the surface of liquid helium

We study radio frequency absorption spectra of the 2D electron system at the surface of liquid helium, by working at fixed frequency and scanning the electron areal density. We observe the liquid to solid transition of the 2D electron system. In the solid phase, we observe two series of signals of the coupled electron-ripplon vibration spectrum. The interpretation of these signals leads to a determination of the Debye-Waller factor W1, and of the ripplon relaxation time.Nous étudions les spectres d'absorption du système d'électrons à deux dimensions formé par les électrons à la surface de l'hélium liquide, en travaillant à fréquence fixe et en balayant la densité électronique. Nous observons la transition liquide-solide du système d'électrons à deux dimensions. Dans la phase solide, nous observons deux séries de signaux du spectre des vibrations couplées électron-ripplon. L'interprétation de ces signaux nous permet de déterminer le facteur de Debye-Waller W1, et le temps de relaxation des ripplons

Observation of liquid-to-crystal transition in a two dimensional electronic system

We have observed the liquid-to-crystal transition in a two dimensional system of electrons at the surface of liquid helium, by studying the absorption signal of the electrons excited by an electric field of a fixed frequency 25 MHz.En étudiant le signal d'absorption des électrons à deux dimensions déposés à la surface de l'hélium liquide et excités par un champ électrique de fréquence fixe 25 MHz, nous avons observé la transition liquidecristal

Smiling expression recognition: the semi-supervised haar training of a fast and frugal system

International audienc

Automatic symmetry detection in well-formed nets

Abstract. Formal verification of complex systems using high-level Petri Nets faces the so-called state-space explosion problem. In the context of Petri nets generated from a higher level specification, this problem is particularly acute due to the inherent size of the considered models. A solution is to perform a symbolic analysis of the reachability graph, which exploits the symmetry of a model. Well-Formed Nets (WN) are a class of high-level Petri nets, developed specifically to allow automatic construction of a symbolic reachability graph (SRG), that represents equivalence classes of states. This relies on the definition by the modeler of the symmetries of the model, through the definition of “static sub-classes”. Since a model is self-contained, these (a)symmetries are actually defined by the model itself. This paper presents an algorithm capable of automatically extracting the symmetries inherent to a model, thus allowing its symbolic study by translating it to WN. The computation starts from the assumption that the model is entirely symmetric, then examines each component of a net to deduce the symmetry break it induces. This translation is transparent to the end-user, and is implemented as a service for the AMI-Net package. It is particularly adapted to models containing large value domains, yielding combinatorial gain in the size of the reachability graph.